0001157523-21-001436.txt : 20211119 0001157523-21-001436.hdr.sgml : 20211119 20211119143111 ACCESSION NUMBER: 0001157523-21-001436 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211118 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211119 DATE AS OF CHANGE: 20211119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CROSS COUNTRY HEALTHCARE INC CENTRAL INDEX KEY: 0001141103 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HELP SUPPLY SERVICES [7363] IRS NUMBER: 134066229 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33169 FILM NUMBER: 211427908 BUSINESS ADDRESS: STREET 1: 6551 PARK OF COMMERCE BOULEVARD, N.W. CITY: BOCA RATON STATE: FL ZIP: 33487 BUSINESS PHONE: 8003472264 MAIL ADDRESS: STREET 1: 6551 PARK OF COMMERCE BOULEVARD, N.W. CITY: BOCA RATON STATE: FL ZIP: 33487 FORMER COMPANY: FORMER CONFORMED NAME: CROSS COUNTRY INC DATE OF NAME CHANGE: 20010521 8-K 1 a52534862.htm CROSS COUNTRY HEALTHCARE, INC. 8-K

UNITED STATES 
 SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
 
FORM 8-K
 
 
 
CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) November 18, 2021
 graphic
 
 
 
Cross Country Healthcare, Inc.
(Exact name of registrant as specified in its charter)
 
 

Delaware
0-33169
13-4066229
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 
6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487
(Address of Principal Executive Office) (Zip Code)

(561) 998-2232
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class Trading Symbol Name of each exchange on which registered
Common stock, par value $0.0001 per share
 CCRN
 The Nasdaq Stock Market LLC

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01   Entry into a Material Definitive Agreement.

On November 18, 2021, Cross Country Healthcare, Inc. (the “Company”) entered into that certain First Incremental Amendment to Term Loan Credit Agreement (the “First Amendment”), by and among the Company, the Guarantors (as defined therein), the Lenders (as defined therein), and Wilmington Trust, National Association, as administrative agent and collateral agent, to amend certain terms of the Term Loan Credit Agreement (the “Term Loan Credit Agreement”), dated as of June 8, 2021. Pursuant to the First Amendment, the Lenders agreed to provide to the Company an incremental term loan in an aggregate amount equal to $75,000,000 (the “Term Loan”). Additionally, the First Amendment increased the aggregate amount of all Increases (as defined in the Term Loan Credit Agreement) to be no greater than $115,000,000. All other terms, conditions, covenants, and pricing of the Term Loan Credit Agreement remain the same. In conjunction with the First Amendment, Wells Fargo Bank, National Association, as First Lien Agent, and Wilmington Trust, National Association, as Second Lien Agent, entered into that certain First Amendment to Intercreditor Agreement, effective as of November 18, 2021, to amend the Intercreditor Agreement, dated as of June 8, 2018, which sets forth the lien priority, relative rights, and other creditors’ rights issues in respect of the collateral lenders.

In connection with the Term Loan, on November 18, 2021, the Company also entered into Amendment No. 4 to ABL Credit Agreement (“ABL Amendment No. 4”), which amends that certain ABL Credit Agreement, dated October 25, 2019, by and among the Company and certain of its domestic subsidiaries as borrowers, certain of its domestic subsidiaries as guarantors, the Lenders (as defined therein), and Wells Fargo Bank, National Association as agent, as amended by Amendment No. 1 to ABL Credit Agreement, dated June 30, 2020, Amendment No. 2 to ABL Credit Agreement, dated March 8, 2021, and Amendment No. 3 to ABL Credit Agreement, dated as of June 8, 2021 (the “ABL Credit Agreement”). Pursuant to ABL Amendment No. 4, the Permitted Indebtedness (as defined in the ABL Credit Agreement) arising pursuant to the Term Loan Agreement (as defined in the ABL Credit Agreement) was increased to $175,000,000.

The foregoing summaries of the First Amendment and ABL Amendment No. 4 do not purport to be complete and are qualified in their entireties by reference to the full texts of the First Amendment and ABL Amendment No. 4 that are filed herewith as Exhibit 10.1 and Exhibit 10.2, respectively, and are incorporated herein by reference.

 Item 2.03   Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a  Registrant.

The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.

Item 9.01   Financial Statements and Exhibits.

(d)                  Exhibits

          
Exhibit
Description
     
 
 
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 

 
 
CROSS COUNTRY HEALTHCARE, INC.
 
 
 
 
       
 
 
 
 
Dated:
November 19, 2021
By:
/s/ William J. Burns
  
 
 
 
William J. Burns
 
 
 
Executive Vice President & Chief Financial Officer
 
 
 
 







EX-10.1 2 a52534862ex10_1.htm EXHIBIT 10.1
Exhibit 10.1

 FIRST INCREMENTAL AMENDMENT TO TERM LOAN CREDIT AGREEMENT
 
This FIRST INCREMENTAL AMENDMENT TO CREDIT AGREEMENT, dated as of November 18, 2021 (this “Amendment”), is entered into by and among the Lenders (as defined below), WILMINGTON TRUST, NATIONAL ASSOCIATION (“Wilmington Trust”) as administrative agent (in such capacity, “Administrative Agent”) and as collateral agent (in such capacity, “Collateral Agent”), CROSS COUNTRY HEALTHCARE, INC., a Delaware corporation (“Borrower”), and the Guarantors party hereto (each, a “Guarantor” and individually and collectively, jointly and severally, the “Guarantors”). Capitalized terms used herein and not otherwise defined shall have the meaning assigned thereto in the Credit Agreement (as defined below).
 
WHEREAS, reference is hereby made to the Term Loan Credit Agreement, dated as of June 8, 2021 (the “Initial Closing Date”) (as amended, restated, supplemented or otherwise modified prior to giving effect to this Amendment, the “Existing Credit Agreement” and, the Existing Credit Agreement as amended by this Amendment, the “Credit Agreement”), among Borrower, the Guarantors party thereto, the lenders party thereto (the “Lenders”), the Administrative Agent and the Collateral Agent;
 
WHEREAS, Borrower has requested that (i) one or more of the Lenders (such Lenders, the “Incremental Lenders”) provide an Incremental Term Facility in an aggregate amount equal to $75,000,000 (such Term Loans provided under such Incremental Term Facility, the “First Amendment Incremental Term Loans”) and (ii) the Required Lenders amend the cap set forth in Section 2.14(a)(i) to permit the aggregate amount of all Increases to be no greater than $115,000,000;
 
WHEREAS, the Incremental Lenders have indicated their willingness to make the First Amendment Incremental Term Loans on the terms and subject to the conditions of this Amendment in the amounts set forth opposite each such Incremental Lender’s name under the heading “First Amendment Incremental Term Loan Commitments” on Schedule C-1 hereto; and
 
WHEREAS, the parties hereto are willing, on the terms and subject to the conditions stated below, to amend the Existing Credit Agreement as hereinafter set forth.
 
NOW, THEREFORE, in consideration of the premises and agreements, provisions and covenants herein contained, the parties hereto hereby agree as follows:
 
SECTION 1. Defined Terms; References. The rules of construction and other interpretive provisions specified in Sections 1.1, 1.3, 1.4, 1.5, and 1.6 of the Existing Credit Agreement shall apply to this Amendment, including terms defined in the preamble and recitals hereto.
 
SECTION 2. Incremental Amendment.
 
(a)            This Amendment is an amendment to incur an additional term loan facility as described in Section 2.14(a) of the Existing Credit Agreement which shall be deemed incurred pursuant to this Amendment.  Subject to the satisfaction of the conditions set forth in Section 4 below, each Incremental Lender agrees, effective as of the First Amendment Effective Date, to extend the term loan commitments set forth opposite such Incremental Lender’s name under the heading “First Amendment Incremental Term Loan Commitments” on Schedule C-1 hereto on the First Amendment Effective Date (the “First Amendment Incremental Term Loan Commitments”).  From and after the First Amendment Effective Date, (i) each Incremental Lender shall be an “Lender” for all purposes under the Credit Agreement and the other Loan Documents, and shall have all of the rights and obligations of a Lender under the Credit Agreement and the other Loan Documents (ii) the First Amendment Incremental Term Loan Commitment of each Incremental Lender shall be a “Commitment” for all purposes under the Credit Agreement and the other Loan Documents and Schedule C-1 of the Existing Credit Agreement shall be deemed amended and supplemented to include such Schedule C-1 hereto and (iii) the First Amendment Incremental Term Loans of the Incremental Lenders shall be “Term Loans” (and have the same terms (including with respect to Guarantees and Collateral and rights to payment and prepayment) as the Term Loans made on the Initial Closing Date), for all purposes under the Credit Agreement and the other Loan Documents.  The First Amendment Incremental Term Loans shall be made in a single Borrowing on the First Amendment Effective Date.
 

(b)            For the avoidance of doubt, the terms and provisions of the First Amendment Incremental Term Loans shall be identical to the Term Loans made on the Initial Closing Date, including the same repayment terms and the same Applicable Margin and Prepayment Premium terms set forth in the Existing Credit Agreement.
 
(c)            Notwithstanding anything to the contrary in the Credit Agreement, (i) the First Amendment Incremental Term Loans will be borrowed at the LIBOR Option, (ii) the initial Interest Period applicable to the First Amendment Incremental Term Loans shall end on the same day as the Interest Period in effect on the First Amendment Effective Date with respect to the Term Loans made on the Initial Closing Date and (iii) the LIBOR Rate with respect to such initial Interest Period shall be identical to the LIBOR Rate for such Interest Period in effect on the First Amendment Effective Date with respect to the Term Loans made on the Initial Closing Date.
 
(d)            Notwithstanding anything to the contrary in Section 2.14 of the Existing Credit Agreement, the execution and delivery of this Amendment by Borrower and the satisfaction of all conditions precedent to effectiveness of this Amendment pursuant to Section 4 hereof shall be deemed to constitute a properly delivered and accepted written notice by Borrower in accordance with the terms of Section 2.14(a) of the Existing Credit Agreement.
 
(e)            The Borrower and the Lenders party hereto hereby waive the procedures set forth in Section 2.14(b) of the Credit Agreement and acknowledge and agree that each Lender has been provided the option to provide up to its Pro Rata Share of the First Amendment Incremental Term Loans.
 
(f)            Notwithstanding anything to the contrary contained herein, if funding of the First Amendment Incremental Term Loans shall not have occurred on the First Amendment Effective Date, this Amendment shall immediately terminate on the day after the First Amendment Effective Date and shall no longer be in force and effect, and the First Amendment Incremental Term Loan Commitments hereunder shall automatically terminate on such date.
 
SECTION 3. Amendments to Credit Agreement.  The Existing Credit Agreement is, subject to satisfaction of each of the conditions set forth in Section 4 herein, amended as of the First Amendment Effective Date, as follows:
 
(a)             the following defined terms and related definitions shall be added to Section 1.01 of the Existing Credit Agreement in proper alphabetical order:
 

“First Amendment” means that certain First Incremental Amendment to Credit Agreement, dated as of November 18, 2021, by and among Borrower, the other Loan Parties party thereto, the Lenders party thereto and the Administrative Agent.
 
“First Amendment Incremental Term Loans” has the meaning set forth in the First Amendment.
 
“First Amendment Effective Date” has the meaning provided in the First Amendment.
 
(b)            Section 2.4(d)(i) of the Existing Credit Agreement shall be amended and restated in its entirety to read:
 
(i)            In addition to any other mandatory prepayments pursuant to this Section 2.4(d), on each date set forth below, Borrower shall be required to repay, to the Administrative Agent for the ratable account of the Lenders, that principal amount of the Term Loans (including, for the avoidance of doubt, the First Amendment Incremental Term Loans), to the extent then outstanding, as is set forth opposite each such date below:
 
Date
Amount
   
December 31, 2021
$437,500
March 31, 2022
$437,500
June 30, 2022
$437,500
September 30, 2022
$437,500
December 31, 2022
$437,500
March 31, 2023
$437,500
June 30, 2023
$437,500
September 30, 2023
$437,500
December 31, 2023
$437,500
March 31, 2024
$437,500
June 30, 2024
$437,500
September 30, 2024
$437,500
December 31, 2024
$437,500
March 31, 2025
$437,500
June 30, 2025
$437,500
September 30, 2025
$437,500
December 31, 2025
$437,500
March 31, 2026
$437,500
June 30, 2026
$437,500
September 30, 2026
$437,500
December 31, 2026
$437,500
March 31, 2027
$437,500
Maturity Date for Term Loans
All unpaid aggregate
principal amounts of any
outstanding Term Loans


(c)            Section 2.14(a)(i) of the Existing Credit Agreement shall be amended and restated in its entirety to read:
 
(i)            the aggregate amount of all such increases shall not exceed $115,000,000,
 
SECTION 4. Conditions to Effectiveness.  The effectiveness of the First Amendment Incremental Term Loan Commitments, the funding of the First Amendment Incremental Term Loans and the effectiveness of the amendments and waivers to the Existing Credit Agreement set forth herein are each subject to the satisfaction of all of the following conditions precedent (the date on which such conditions shall have been satisfied or waived, the “First Amendment Effective Date”):
 
(a)  the Incremental Lenders and the Administrative Agent shall have received executed counterparts of this Amendment from the Loan Parties, each Incremental Lender, the Agents and the Required Lenders;

(b)  the Incremental Lenders shall have received executed counterparts of the fee letter dated as of the First Amendment Effective Date between the Borrower and the Incremental Lenders (the “First Amendment Fee Letter”);

(c)  no Default or Event of Default shall have occurred and be continuing on the First Amendment Effective Date immediately before or after giving effect to this Amendment;

(d)  the representations and warranties of each Loan Party or its Subsidiaries contained in the Credit Agreement or in the other Loan Documents shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) on and as of the First Amendment Effective Date, as though made on and as of such date (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) as of such earlier date);

(e)  the Administrative Agent and BXC Representative shall have received fully executed counterparts of (i) the First Amendment to the Intercreditor Agreement (the “First Amendment to Intercreditor Agreement”), and (ii) Amendment No. 4 to ABL Credit Agreement, in each case, in form and substance reasonably satisfactory to the BXC Representative;

(f)  the Administrative Agent and BXC Representative shall have received a certificate from the Secretary of each Loan Party (i) attesting to the resolutions of such Loan Party’s board of directors or equivalent body authorizing its execution, delivery, and performance of this Amendment, (ii) authorizing specific officers of such Loan Party to execute the same, and (iii) attesting to the incumbency and signatures of such specific officers of such Loan Party;

(g)  the Administrative Agent and BXC Representative shall have received copies of each Loan Party’s Organization Documents, as amended, modified, or supplemented to the First Amendment Effective Date, which Organization Documents shall be (i) certified by the Secretary or an Authorized Person of such Loan Party, and (ii) with respect to Organization Documents that are charter documents, certified as of a recent date (not more than thirty (30) days prior to the Closing Date) by the appropriate governmental official;


(h)  the Administrative Agent and BXC Representative shall have received a certificate of status with respect to each Loan Party, dated within thirty (30) days of the First Amendment Effective Date, such certificate to be issued by the appropriate officer of the jurisdiction of organization of such Loan Party, which certificate shall indicate that such Loan Party is in good standing in such jurisdiction;

(i)  the Administrative Agent and BXC Representative shall have received a solvency certificate, in form and substance reasonably satisfactory to BXC Representative, certifying as to the solvency of the Loan Parties taken as a whole after giving effect to the transactions contemplated under the Agreement on the First Amendment Effective Date;

(j)  the Administrative Agent and BXC Representative shall have received favorable opinions of counsel to the Loan Parties in form and substance reasonably satisfactory to BXC Representative addressed to Administrative Agent and Lenders with respect to the Loan Parties, this Amendment and such other matters as BXC Representative shall reasonably request (which such opinions shall expressly permit reliance by permitted successors and assigns of the addressees thereof);

(k)  the Administrative Agent shall have received a Committed Term Loan Notice in accordance with Section 2.3(a) of the Credit Agreement;

(l)  the Incremental Lenders shall have received (or contemporaneously with the First Amendment Effective Date) the fees required to be paid pursuant to the First Amendment Fee Letter;

(m) the Administrative Agent shall have received (or shall receive contemporaneously with the First Amendment Effective Date) an amendment fee in the amount of $5,000 in respect of this Amendment;

(n)  Borrower shall have paid all Lender Group Expenses incurred in connection with the transactions evidenced by this Amendment, including the reasonable, documented and invoiced legal fees of one firm of counsel for each of (i) the Agents and (ii) the BXC Representative.

SECTION 5. Representations and Warranties of Loan Parties. Borrower and each other Loan Party represent and warrant as follow:
 
(a)            As to each Loan Party, the execution, delivery, and performance by such Loan Party of this Amendment has been duly authorized by all necessary action on the part of such Loan Party.
 
(b)            this Amendment has been duly executed and delivered by each Loan Party that is a party thereto and is the legally valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its respective terms, except as enforcement may be limited by equitable principles or by bankruptcy, insolvency, reorganization, moratorium, or similar laws relating to or limiting creditors’ rights generally; and
 

(c)            the representations and warranties of each Loan Party or its Subsidiaries contained in the Credit Agreement or in the other Loan Documents are true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) on and as of the First Amendment Effective Date, as though made on and as of such date (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties are true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) as of such earlier date).
 
SECTION 6. Effect of Amendment; Etc.  Except as expressly set forth herein, this Amendment and the foregoing waivers shall be effective only to the extent specifically set forth herein and such waivers shall not (a) be construed as a waiver of any breach, Default or Event of Default known or unknown to Agents and/or the Lenders, (b) affect the right of the Lenders to demand compliance by the Loan Parties with all terms and conditions of the Credit Agreement and the Loan Documents, except as specifically waived by the terms hereof, (c) be deemed a waiver of any transaction or future action on the part of the Loan Parties requiring the Lenders’ or the Required Lenders’ consent or approval under the Credit Agreement or the Loan Documents, (d) be deemed or construed to be a waiver or release of, or a limitation upon, Agents’ or the Lenders’ exercise of any rights or remedies under the Credit Agreement or any Loan Document, whether arising as a consequence of any Default or Event of Default which may now exist or otherwise, all such rights and remedies hereby being expressly reserved, or (e) be deemed to waive or modify any other requirement or term of the Credit Agreement or any of the Loan Documents.  Without limiting the foregoing, Borrower acknowledges and agrees that each Loan Document to which it is a party is hereby confirmed and ratified and shall remain in full force and effect according to its respective terms (in the case of the Existing Credit Agreement, as amended hereby).  On and as of the First Amendment Effective Date, (i) this Amendment shall be a Loan Document and (ii) each reference in the Credit Agreement to “this Amendment”, “hereof”, “hereunder”, “herein” and “hereby” and each other similar reference, and each reference in any other Loan Document to “the Credit Agreement”, “thereof”, “thereunder”, “therein” or “thereby” or any other similar reference to the Credit Agreement shall refer to the Existing Credit Agreement as amended hereby.
 
SECTION 7. Choice of Law and Venue; Jury Trial Waiver; Judicial Reference Provision.  The provisions of Section 12 to the Credit Agreement are hereby incorporated by reference as if such Section was fully set forth herein.
 
SECTION 8. Reaffirmation of the Loan Parties.  Each Loan Party hereby confirms and agrees that, notwithstanding the effectiveness of this Amendment, each Loan Document to which such Loan Party is a party is, and the obligations of such Loan Party contained in the Existing Credit Agreement, this Amendment or in any other Loan Document to which it is a party are, and shall continue to be, in full force and effect and are hereby ratified and confirmed in all respects, in each case as amended, modified, or waived by this Amendment.  For greater certainty and without limiting the foregoing, each Loan Party hereby confirms that the existing security interests granted by such Loan Party in favor of the Administrative Agent for the benefit of, among others, the Lenders pursuant to the Loan Documents in the Collateral described therein shall continue to secure the obligations of the Loan Parties under the Credit Agreement and the other Loan Documents as and to the extent provided in the Loan Documents.
 
SECTION 9. Notices; Successors.  All communications and notices hereunder shall be given as provided in the Credit Agreement.  The terms of this Amendment shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns.
 

SECTION 10. Severability. Any provision of this Amendment that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
 
SECTION 11. Counterparts.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Amendment.  Delivery of an executed counterpart of this Amendment by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Amendment.  Any party delivering an executed counterpart of this Amendment by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Amendment.  The words “execution,” “signed,” “signature,” and words of like import in this Amendment shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
 
SECTION 12. Incorporation of Credit Agreement Miscellaneous Provisions. Each of the provisions provided in the following sections of the Credit Agreement is hereby incorporated herein by this reference with the same effect as though set forth in its entirety herein, mutatis mutandis, and as if “this Amendment” in any such provision read “this Amendment”: Section 17.1 (Effectiveness) and Section 17.9 (Confidentiality).
 
SECTION 13. Agents.  The Lenders party hereto, constituting all of the Lenders, hereby (i) direct each of the Agents to execute and deliver this Amendment and the First Amendment to Intercreditor Agreement and (ii) acknowledge and agree that (x) the direction in this Section 13 constitutes a direction from the Lenders under the provisions of Section 15 of the Credit Agreement and (y) the Agents shall be entitled to all of the rights, benefits, exculpations and protections set forth in the Credit Agreement (including, without limitation, those set forth in Section 15 of the Credit Agreement (including Sections 15.3 and 15.7 of the Credit Agreement)) in connection with any and all actions taken by the Agents in accordance with such direction.
 
[Remainder of Page Intentionally Blank]
 




IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective proper and duly authorized officers as of the day and year first above written.
 

BORROWER:                                                                         
 
CROSS COUNTRY HEALTHCARE, INC.,
a Delaware corporation

 
By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: Co-Founder, CEO and President


GUARANTORS:
 
CEJKA SEARCH, INC.,
a Delaware corporation


By: /s/ William Burns
Name: William Burns
Title: Vice President
 
CROSS COUNTRY STAFFING, INC.,
a Delaware corporation

 
By: /s/ William Burns
Name: William Burns
Title: Vice President
 
ASSIGNMENT AMERICA, LLC.,
a Delaware limited liability company

  By: /s/ William Burns
Name: William Burns
Title: Vice President


[Signature Page to First Incremental Amendment]
 
 
TRAVEL STAFF, LLC,
a Delaware limited liability company

 
By: /s/ William Burns
Name: William Burns
Title: Vice President
 
 
OWS, LLC,
a Delaware limited liability company

 
By: /s/ William Burns
Name: William Burns
Title: Vice President
 
 
NEW MEDISCAN II, LLC,
a California limited liability company

 
By: /s/ William Burns
Name: William Burns
Title: Vice President


[Signature Page to First Incremental Amendment]

 
MEDICAL DOCTOR ASSOCIATES, LLC,
a Delaware limited liability company
 
 
By: /s/ William Burns
Name: William Burns
Title: Vice President


[Signature Page to First Incremental Amendment]

 
MDA HOLDINGS, INC.,
a Delaware corporation
 
 
By: /s/ William Burns
Name: William Burns
Title: Vice President
 
CREDENT VERIFICATION AND LICENSING SERVICES, LLC,
a Delaware limited liability company

 
By: /s/ William Burns
Name: William Burns
Title: Vice President


[Signature Page to First Incremental Amendment]

  WILMINGTON TRUST, NATIONAL ASSOCIATION,
as Administrative Agent and Collateral Agent

  By:
/s/ Joseph B. Feil
Name: Joseph B. Feil
Title: Vice President

 
[Signature Page to First Incremental Amendment]

 
BLACKSTONE ALTERNATIVE CREDIT ADVISORS LP,
as BXC Representative
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory
 
BGSL BRECKENRIDGE FUNDING LLC,
as a Lender

By: Blackstone Secured Lending Fund, as sole member
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory


 
BLACKSTONE PRIVATE CREDIT FUND,
as an Incremental Lender
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory

 
 
BCRED GRANITE PEAK FUNDING LLC,
BCRED SUMMIT PEAK FUNDING LLC,
as both Lenders and Incremental Lenders
 
By: Blackstone Private Credit Fund, as sole member

 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory


[Signature Page to First Incremental Amendment]
 
BXC JADE SUB 1 LLC, as a Lender
 
By: BXC Jade Topco 1 LP, its sole member

By:  BXC Jade Associates LLC, its general partner

 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory
 
BXC JADE SUB 2 LLC, , as a Lender
 
By: BXC Jade Topco 2 LP, its sole member
 
By:  BXC Jade Associates LLC, its general partner
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory
 
BXC JADE SUB 3 LLC, , as a Lender
 
By: BXC Jade Topco 3 LP, its sole member
 
By:  BXC Jade Associates LLC, its general partner
 
 
By:  /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory

 
 
BXC JADE SUB 4 LLC, Lender
 
By: BXC Jade Topco 4 LP, its sole member
 
By:  BXC Jade Associates LLC, its general partner
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory


[Signature Page to First Incremental Amendment]
BXC JADE SUB 5-B LLC, as an Incremental Lender
 
By: BXC Jade Top Sub 5-B LLC, its sole member
 
By:  BXC Jade Topco 5-B LP, its sole member
 
By:  BXC Jade Associates LLC, its general partner
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory
 
BXC JADE SUB 6-B LLC, as an Incremental Lender
 
By: BXC Jade Top Sub 6-B LLC, its sole member
 
By:  BXC Jade Topco 6-B LP, its sole member
 
By:  BXC Jade Associates LLC, its general partner
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory
 
BXC JADE SUB 7-B LLC, as an Incremental Lender
 
By: BXC Jade Top Sub 7-B LLC, its sole member
 
By:  BXC Jade Topco 7-B LP, its sole member
 
By:  BXC Jade Associates LLC, its general partner
 
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory

 
 
BXC JADE SUB 8-B LLC, as an Incremental Lender
 
By: BXC Jade Top Sub 8 B LLC, its sole member
 
By:  BXC Jade Topco 8-B LP, its sole member
 
By:  BXC Jade Associates LLC, its general partner
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory


[Signature Page to First Incremental Amendment]

 
BXC JADE SUB 9-B LLC, as an Incremental Lender
 
By: BXC Jade Top Sub 9-B LLC, its sole member
 
By:  BXC Jade Topco 9-B LP, its sole member
 
By:  BXC Jade Associates LLC, its general partner
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory

 
 
BXC JADE SUB 10-B LLC, as an Incremental Lender
 
By: BXC Jade Top Sub 10-B LLC, its sole member
 
By:  BXC Jade Topco 10-B LP, its sole member
 
By:  BXC Jade Associates LLC, its general partner
 
 
By: /s/ Marisa J. Beeney
Name: Marisa J. Beeney
Title: Authorized Signatory


[Signature Page to First Incremental Amendment]

Schedule C-1
Commitments


Lender
First Amendment
Incremental Term
Loan Commitments
  
First Amendment
Incremental Term Loan
Commitment Percentage
  
BCRED Granite Peak Funding LLC
$14,914,234.85
  
19.885646467
 %
BCRED Summit Peak Funding LLC
$40,471,530.25
  
53.962040333
 %
Blackstone Private Credit Fund
$3,600,000.00
  
4.800000000
 %
BXC Jade Sub 5-B LLC
$2,669,039.15
  
3.558718867
 %
BXC Jade Sub 6-B LLC
$2,669,039.15
  
3.558718867
 %
BXC Jade Sub 7-B LLC
$2,669,039.15
  
3.558718867
 %
BXC Jade Sub 8-B LLC
$2,669,039.15
  
3.558718867
 %
BXC Jade Sub 9-B LLC
$2,669,039.15
  
3.558718867
 %
BXC Jade Sub 10-B LLC
$2,669,039.15
  
3.558718867
 %
Total Commitments:
$75,000,000.00
  
100.000000000
 %


EX-10.2 3 a52534862ex10_2.htm EXHIBIT 10.2
Exhibit 10.2

AMENDMENT NO. 4 TO ABL CREDIT AGREEMENT
 
AMENDMENT NO. 4 TO ABL CREDIT AGREEMENT, dated as of November 18, 2021 (this “Amendment No. 4”), is by and among Wells Fargo Bank, National Association, a national banking association, as administrative agent for each member of the Lender Group and the Bank Product Providers (in such capacity, together with its successors and assigns in such capacity, “Agent”), Wells Fargo Bank, National Association, a national banking association, in its capacity as sole lead arranger (in such capacity, together with its successors and assigns in such capacity, the “Lead Arranger”), Wells Fargo Bank, National Association, a national banking association as sole book runner (in such capacity, together with their successors and assigns in such capacity, the “Book Runner”), Wells Fargo Bank, National Association, a national banking association, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), Cross Country Healthcare, Inc., a Delaware corporation (“Parent”), Cejka Search, Inc., a Delaware corporation (“Cejka”), Cross Country Staffing, Inc., a Delaware corporation (“Cross Country Staffing”), Assignment America, LLC., a Delaware limited liability company (“Assignment America”), Travel Staff, LLC, a Delaware limited liability company (“Travel Staff”), Medical Doctor Associates, LLC, a Delaware limited liability company (“Medical Doctor”), OWS, LLC, a Delaware limited liability company (“OWS”), New Mediscan II, LLC, a California limited liability company (“New Mediscan” and together with Parent, Cejka, Cross Country Staffing, Assignment America, Travel Staff, Medical Doctor, OWS and those additional persons that hereafter become parties thereto as Borrowers in accordance with the terms thereof, each, a “Borrower” and individually and collectively, jointly and severally, the “Borrowers”), MDA Holdings, Inc., a Delaware corporation (“MDA Holdings”), Credent Verification and Licensing Services, LLC, a Delaware limited liability company (“Credent Verification” and together with MDA Holdings and those additional persons that hereafter become parties thereto as Guarantors in accordance with the terms thereof, each, a “Guarantor” and individually and collectively, jointly and severally, the “Guarantors”).
 
W I T N E S S E T H:
 
WHEREAS, Agent, Lenders, Borrowers and Guarantors have entered into senior secured asset-based revolving credit facility pursuant to which Lenders (or Agent on behalf of Lenders) have made and may make loans and advances and provide other financial accommodations to Borrowers as set forth in the ABL Credit Agreement, dated as of October 25, 2019, by and among Agent, Lenders, Borrowers and Guarantors, as amended by Amendment No. 1 to ABL Credit Agreement, dated as of June 30, 2020, by and among Agent, Lenders, Borrowers and Guarantors, Amendment No. 2 to ABL Credit Agreement and Amendment No. 1 to Guaranty and Security Agreement, dated as of March 8, 2021, by and among Agent, Lenders, Borrowers and Guarantors and Amendment No. 3 to ABL Credit Agreement, dated as of June 8, 2021, by and among Agent, Lenders, Borrowers and Guarantors (as the same is amended hereby and may from time to time hereafter be further amended, modified, supplemented, extended, renewed, restated or replaced, the “Credit Agreement”);
 
WHEREAS, Borrowers and Guarantors have requested that Agent and Lenders agree to certain amendments to the Credit Agreement and Security Agreement and Agent and Lenders are willing to agree to such amendments subject to the terms and conditions contained herein;
 
WHEREAS, Agent, Lenders, Borrowers and Guarantors intend to evidence such amendments pursuant to the terms hereof;
 
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements and covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
 

1.    Amendments to Credit Agreement.
 
1.1.    Additional Definitions.  The Credit Agreement is hereby amended to include, in addition and not in limitation, the following definitions:
 
 “Amendment No. 4” means Amendment No. 4 to ABL Credit Agreement, dated as of November 18, 2021, by and among Agent, Lenders, Borrowers and Guarantors, as the same now exists or may hereafter be amended, amended and restated, modified, supplemented, extended, renewed, restated or replaced.
 
“Amendment No. 4 Effective Date” means the first date upon which each of the conditions set forth in Section 4 of the Amendment No. 4 have been satisfied (or waived in writing).
 
“First Amendment to Intercreditor Agreement” means the First Amendment to Intercreditor Agreement, dated as of November 18, 2021, by and among Agent and Term Loan Agent, as acknowledged and agreed to by Loan Parties.
 
“First Amendment to Term Loan Credit Agreement” means the First Incremental Amendment to Credit Agreement, dated as of November 18, 2021, by and among Term Loan Agent, Term Loan Lenders and Loan Parties.
 
1.2.    Amendment to Definition.  Clause (r) of the definition of the term “Permitted Indebtedness” in the Credit Agreement is hereby deleted in its entirety and replaced with the following:
 
(r)  Indebtedness under the Term Loan Agreement (including Refinancing Indebtedness in respect thereof in accordance with the Intercreditor Agreement) in an aggregate principal amount outstanding at any time not to exceed $175,000,000 (as such amount may be increased in accordance with the Intercreditor Agreement),
 
1.3.    Interpretation.  For purposes of this Amendment No. 4, all terms used herein which are not otherwise defined herein, including but not limited to, those terms used in the recitals hereto, shall have the respective meanings assigned thereto in the Credit Agreement.
 
2.    [Reserved].
 
3.    Representations, Warranties and Covenants.  Each Loan Party, jointly and severally, represents and warrants with and to Agent and Lenders as follows, which representations and warranties shall survive the execution and delivery hereof:
 
3.1.   This Amendment No. 4 has been duly executed and delivered by each Loan Party that is party hereto.  This Amendment No. 4 constitutes a legal, valid and binding obligation of each Loan Party, enforceable against such Loan Party that is party hereto in accordance with its terms, except as enforcement may be limited by equitable principles or by bankruptcy, insolvency, reorganization, moratorium, or similar laws relating to or limiting creditors' rights generally.
 
3.2.    The representations and warranties of each Loan Party or its Subsidiaries contained in the Credit Agreement, the Security Agreement or any of the other Loan Documents shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality or Material Adverse Effect (or words of similar import) in the text thereof) on and as of the date hereof, as though made on and as of such date (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality or Material Adverse Effect (or words of similar import in the text thereof) as of such earlier date).
 

3.3.    Loan Parties have delivered to Agent a complete and correct copy of the First Amendment to the Term Loan Credit Agreement, including all schedules and exhibits thereto, as executed on or before the Amendment No. 4 Effective Date.
 
3.4.    No Default or Event of Default exists or has occurred and is continuing as of the date of, and after giving effect to, this Amendment No. 4.
 
4.    Conditions Precedent.  This Amendment No. 4 shall be effective upon the satisfaction of each of the following conditions precedent:
 
4.1.    Agent shall have received each of the following:
 
(a)    this Amendment No. 4, duly authorized, executed and delivered by the Required Lenders and Loan Parties;
 
(b)    the First Amendment to Term Loan Credit Agreement duly authorized, executed and delivered by the Term Loan Agent, Term Loan Lenders and Loan Parties;
 
(c)    the First Amendment to the Intercreditor Agreement duly authorized, executed and delivered by the Term Loan Agent and Loan Parties;
 
4.2.    as of the date of this Amendment No. 4, and after giving effect thereto, no Default or Event of Default shall exist or have occurred and be continuing;
 
4.3.    each of the conditions set forth in this Section 3 shall be satisfied on or before November 30,  2021.
 
5.    Effect of Amendment No. 4.  Except as expressly set forth herein and in prior amendments, no other amendments, changes or modifications to the Loan Documents are intended or implied, and in all other respects the Loan Documents are hereby specifically ratified, restated and confirmed by all parties hereto as of the effective date hereof and the Loan Parties shall not be entitled to any other or further amendment by virtue of the provisions of this Amendment No. 4 or with respect to the subject matter of this Amendment No. 4.  To the extent of conflict between the terms of this Amendment No. 4 and the other Loan Documents, the terms of this Amendment No. 4 shall control.  The Credit Agreement and this Amendment No. 4 shall be read and construed as one agreement.  This Amendment No. 4 is a Loan Document.  The Credit Agreement remains in full force and effect, and nothing contained in this Amendment No. 4 will constitute a waiver of any right, power or remedy under the Credit Agreement, the Security Agreement or any other Loan Document.
 
6.    Governing Law.  The validity, interpretation and enforcement of this Amendment No. 4 and any dispute arising out of the relationship between the parties hereto whether in contract, tort, equity or otherwise, shall be governed by the internal laws of the State of New York but excluding any principles of conflicts of law or other rule of law that would cause the application of the law of any jurisdiction other than the laws of the State of New York.
 

7.    Jury Trial Waiver.    LOAN PARTIES, AGENT AND LENDERS EACH HEREBY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS AMENDMENT NO. 4 OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AMENDMENT NO. 4 OR THE TRANSACTIONS RELATED HERETO OR THERETO IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE.  LOAN PARTIES, AGENT AND LENDERS EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT EACH LOAN PARTY, AGENT OR LENDER MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AMENDMENT NO. 4 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.
 
8.    Binding Effect.  This Amendment No. 4 shall be binding upon and inure to the benefit of each of the parties hereto and their respective successors and assigns.
 
9.    Waiver, Modification, Etc.  No provision or term of this Amendment No. 4 may be modified, altered, waived, discharged or terminated orally, but only by an instrument in writing executed by the party against whom such modification, alteration, waiver, discharge or termination is sought to be enforced.
 
10.    Further Assurances.  The Loan Parties shall execute and deliver such additional documents and take such additional action as may be reasonably requested by Agent to effectuate the provisions and purposes of this Amendment No. 4.
 
11.    Entire Agreement.  This Amendment No. 4, the Credit Agreement and the other Loan Documents represent the entire agreement and understanding concerning the subject matter hereof among the parties hereto, and supersedes all other prior agreements, understandings, negotiations and discussions, representations, warranties, commitments, proposals, offers and contracts concerning the subject matter hereof, whether oral or written.
 
12.    Headings.  The headings listed herein are for convenience only and do not constitute matters to be construed in interpreting this Amendment No. 4.
 
13.    Counterparts.  This Amendment No. 4, any documents executed in connection herewith and any notices delivered under this Amendment No. 4, may be executed by means of (i) an electronic signature that complies with the federal Electronic Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic Transactions Act, or any other relevant and applicable electronic signatures law; (ii) an original manual signature; or (iii) a faxed, scanned, or photocopied manual signature.  Each electronic signature or faxed, scanned, or photocopied manual signature shall for all purposes have the same validity, legal effect, and admissibility in evidence as an original manual signature. Agent reserves the right, in its sole discretion, to accept, deny, or condition acceptance of any electronic signature on this Amendment No. 4 or on any notice delivered to Agent under this Amendment No. 4.  This Amendment No. 4 and any notices delivered under this Amendment No. 4 may be executed in any number of counterparts, each of which shall be deemed to be an original, but such counterparts shall, together, constitute only one instrument.  Delivery of an executed counterpart of a signature page of this Amendment No. 4 and any notices as set forth herein will be as effective as delivery of a manually executed counterpart of this Amendment No. 4 or notice.
 
[remainder of page intentionally left blank]





IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 4 to be duly executed and delivered as of the day and year first above written.
 
BORROWERS:                                                                                    
 
CROSS COUNTRY HEALTHCARE, INC.

 
By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: Co-founder, CEO and President
 
CEJKA SEARCH, INC.

 
By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: EVP
 
CROSS COUNTRY STAFFING, INC.

 
By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: EVP


 
ASSIGNMENT AMERICA, LLC

 
By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: EVP


 
TRAVEL STAFF, LLC

  By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: EVP



 
OWS, LLC

 
By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: EVP
 
 
 
NEW MEDISCAN II, LLC

 
By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: Vice President
 
 
MEDICAL DOCTOR ASSOCIATES, LLC

 
By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: EVP
 

GUARANTORS:
 
MDA HOLDINGS, INC.


By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: EVP
 
CREDENT VERIFICATION AND LICENSING SERVICES, LLC

 
By: /s/ Kevin C. Clark
Name: Kevin C. Clark
Title: EVP

 
WELLS FARGO BANK, NATIONAL ASSOCIATION,
a national banking association, as Administrative Agent,
Collateral Agent and as a Lender
 

By:
Name:
/s/ Rina Shinoda
Rina Shinoda
Its Authorized Signatory

 


 
PNC BANK, NATIONAL ASSOCIATION,
as a Lender
 
 
By:
Name:
/s/ Robert Fernandez
Robert Fernandez, Vice President
Its Authorized Signatory



EX-101.SCH 4 ccrn-20211118.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ccrn-20211118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 6 ccrn-20211118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 cc_logo.jpg begin 644 cc_logo.jpg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end XML 8 a52534862_htm.xml IDEA: XBRL DOCUMENT 0001141103 2021-11-18 2021-11-18 false 0001141103 8-K 2021-11-18 Cross Country Healthcare, Inc. DE 0-33169 13-4066229 6551 Park of Commerce Boulevard N.W. Boca Raton FL 33487 561 998-2232 Common stock, par value $0.0001 per share CCRN NASDAQ false false false false false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 18, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 18, 2021
Entity Registrant Name Cross Country Healthcare, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 0-33169
Entity Tax Identification Number 13-4066229
Entity Address, Address Line One 6551 Park of Commerce Boulevard
Entity Address, Address Line Two N.W.
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33487
City Area Code 561
Local Phone Number 998-2232
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001141103
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol CCRN
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://crosscountryhealthcare.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a52534862.htm a52534862ex10_1.htm a52534862ex10_2.htm ccrn-20211118.xsd ccrn-20211118_lab.xml ccrn-20211118_pre.xml cc_logo.jpg http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a52534862.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "a52534862.htm" ] }, "labelLink": { "local": [ "ccrn-20211118_lab.xml" ] }, "presentationLink": { "local": [ "ccrn-20211118_pre.xml" ] }, "schema": { "local": [ "ccrn-20211118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ccrn", "nsuri": "http://crosscountryhealthcare.com/20211118", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a52534862.htm", "contextRef": "c20211118to20211118", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a52534862.htm", "contextRef": "c20211118to20211118", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001157523-21-001436-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-21-001436-xbrl.zip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